Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 59 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• AB154 Combined With AB122 for Recurrent GlioblastomaActive, not recruitingNCT04656535Early Phase 1
• Study of First-line Camrelizumab With or Without Chemotherapy for Advanced Esophageal Squamous Cell CancerStatus unknownNCT04654403Not applicable
• Perioperative Therapy for Hepatocellular CarcinomaTerminatedNCT04653389Phase 2
• A Study to Test Different Doses of BI 765063 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer (Solid Tumors)CompletedNCT04653142Phase 1
• A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With MelanomaTerminatedNCT04653038Phase 1
• Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary SyndromeActive, not recruitingNCT04652960Phase 1
• Tislelizumab in Combination With TACE in Advanced Hepatocellular CarcinomaStatus unknownNCT04652492Phase 2
• Ablation Combined With PD-1 in HCC: Phase II StudyStatus unknownNCT04652440Phase 1/2
• Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical CancerTerminatedNCT04651127Phase 1/2
• BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid TumorsCompletedNCT04649385Phase 1
• A Study of BMS-936558 With SBRT After Induction Chemotherapy in CholangiocarcinomaTerminatedNCT04648319Phase 2
• A Trial of SHR-1316 Maintenance Therapy for Limited Stage Small Cell Lung CancerStatus unknownNCT04647357Phase 2
• A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerCompletedNCT04647344Phase 1/2
• Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics ModelsStatus unknownNCT04646837Phase 1/2
• A Trial of AK104 Plus Anlotinib in NSCLCCompletedNCT04646330Phase 1/2
• ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid TumorsCompletedNCT04645069Phase 1/2
• Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT04644250Phase 2
• Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract CancerCompletedNCT04642664Phase 2
• Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor MalignanciesCompletedNCT04641871Phase 1
• Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical CancerStatus unknownNCT04641728Phase 2
• A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced MelanomaCompletedNCT04640545Phase 1
• A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or AblationActive, not recruitingNCT04639180Phase 3
• Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT04638582Phase 2
• The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D InfectionCompletedNCT04638439Phase 1
• A Phase Ⅱ Study of F520 in Patients With Urothelial CarcinomaStatus unknownNCT04636515Phase 2
• A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular CarcinomaTerminatedNCT04635527Phase 1
• Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)Active, not recruitingNCT04634877Phase 3
• Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) MutationStatus unknownNCT04633902Phase 2
• Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in Cutaneaous Squamous Cell CarcinomaActive, not recruitingNCT04632433Phase 2
• Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBCActive, not recruitingNCT04630730Phase 2
• Investigating Atezolizumab in Newly Diagnosed ER Positive Breast Cancer Patients According to Their AdipOsityWithdrawnNCT04630210Early Phase 1
• HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular CarcinamaStatus unknownNCT04627363Phase 2
• A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced CancersActive, not recruitingNCT04626635Phase 1/2
• Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)CompletedNCT04626518Phase 1/2
• Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)CompletedNCT04626479Phase 1/2
• Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant TreatmentWithdrawnNCT04625699Phase 2
• Neoadjuvant Immunotherapy to ESCCWithdrawnNCT04625543Phase 2
• Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial CancerCompletedNCT04624399Phase 2
• Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)Active, not recruitingNCT04624204Phase 3
• Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell CarcinomaTerminatedNCT04624113Phase 1
• A Study to Evaluate the Tolerance and Pharmacokinetics of TQB2618 Injection in Subjects With Advanced Solid TumorsStatus unknownNCT04623892Phase 1
• A Study of TQB2450 Injection in Subjects With PD-L1 Positive Recurrent or Metastatic Cervical CancerStatus unknownNCT04623333Phase 2
• Lenvatinib and Pembrolizumab in Resectable Mucosal MelanomaStatus unknownNCT04622566Phase 2
• Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung CancerCompletedNCT04622228Phase 2
• Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal OriginStatus unknownNCT04620954Phase 1/2
• Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line ChemotherapyStatus unknownNCT04620837Phase 2
• Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to SurgeryCompletedNCT04620200Phase 2
• A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.TerminatedNCT04619433Phase 3
• A Study of EMB-02 in Participants With Advanced Solid TumorsTerminatedNCT04618393Phase 1/2
• HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTTCompletedNCT04618367Not applicable
• Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line ChemotherapyStatus unknownNCT04613804Phase 2
• A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)CompletedNCT04613674Phase 3
• Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid CancerStatus unknownNCT04612894Phase 2
• A Phase 1/2 Study of Donafenib in Combination With KN046 in Advanced Gastrointestinal TumorsTerminatedNCT04612712Phase 1/2
• A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLCStatus unknownNCT04612673Phase 2
• A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung CancerWithdrawnNCT04611776Phase 2
• Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell CarcinomaTerminatedNCT04611321Phase 1/2
• Concurrent Nivolumab and External Beam Radiation Therapy for Patients With Advanced HCCCompletedNCT04611165Phase 2
• Brentuximab Vedotin With Pembrolizumab in Metastatic Solid TumorsCompletedNCT04609566Phase 2
• Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction AdenocarcinomaStatus unknownNCT04609176Phase 2
• Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS LymphomaActive, not recruitingNCT04609046Phase 1
• A Clinical Study of PD-L1 Antibody ZKAB001 Combined With Capecitabine in Resected Biliary Tract CancerStatus unknownNCT04608786Phase 1
• Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung CancerActive, not recruitingNCT04607954Phase 2
• AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable AngiosarcomaWithdrawnNCT04607200Phase 2
• A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid TumorsActive, not recruitingNCT04606472Phase 1
• Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic LeukemiaActive, not recruitingNCT04606433Phase 1
• Surgical Nivolumab And Ipilimumab For Recurrent GBMActive, not recruitingNCT04606316Phase 1
• Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue SarcomaStatus unknownNCT04606108Phase 2
• Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver CancerActive, not recruitingNCT04605731Phase 1
• 64Cu-DOTA-pembrolizumab PET for the Study of PD1 ExpressionWithdrawnNCT04605614Phase 1
• Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular CarcinomaActive, not recruitingNCT04605185Phase 1
• A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial CarcinomaStatus unknownNCT04603846Phase 1
• A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell CarcinomaCompletedNCT04603248Not applicable
• A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific MarkersTerminatedNCT04603040Phase 2
• Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)Active, not recruitingNCT04602533Phase 2
• Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma (Nasal Type) TrialTerminatedNCT04602065Phase 1/2
• Sintilimab Injection Combined With Concurrent CCRT in Locally Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT04602013Phase 2
• Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell LymphomaStatus unknownNCT04600947Phase 2
• SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 TrialActive, not recruitingNCT04599140Phase 1/2
• A Study of AK112 for Advanced Solid TumorsCompletedNCT04597541Phase 1/2
• NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal AdenocarcinomaTerminatedNCT04594811Phase 1
• Anti-PD-1 Antibody in the Treatment of Patients With Malignant Melanoma of the Female Genital TractStatus unknownNCT04593485Phase 2
• Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction CancerActive, not recruitingNCT04592913Phase 3
• Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate CancerActive, not recruitingNCT04592237Phase 2
• The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingNCT04591431Phase 2
• A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based ChemotherapyCompletedNCT04590599Phase 2
• Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyActive, not recruitingNCT04589845Phase 2
• Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade GliomaStatus unknownNCT04588987Phase 2
• Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLCStatus unknownNCT04586465Phase 2
• Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment FailureActive, not recruitingNCT04586088Phase 2
• Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)SuspendedNCT04585477Phase 2
• A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast CancerCompletedNCT04584112Phase 1
• Neoadjuvant PD-1 in Newly Diagnosed GlioblastomaStatus unknownNCT04583020Phase 2
• Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of MelanomaCompletedNCT04581382Early Phase 1
• Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical CystectomyTerminatedNCT04579133Phase 2
• Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian CancerActive, not recruitingNCT04575961Phase 2
• Nivolumab+Ipilimumab+RT in MSS mCRCStatus unknownNCT04575922Phase 2
• A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy VolunteersCompletedNCT04575311Phase 1
• Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC)Status unknownNCT04574817Phase 2
• A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial CancerCompletedNCT04574284Phase 2

← Immune Checkpoint Inhibitors overview